A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a
safe and effective treatment in patients with FLC. Safety will be measured by looking at the
adverse events that may happen and the efficacy will look at the progression of the disease
over time.